Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sartorius Stedim BiotechCHIX:DIMP 83 1-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 83/100 and a GF Value™ of €202.26 (Fairly Valued). The stock has 8 warning signs investors should review. Among 539 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks worse than 185528.57% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Sartorius Stedim Biotech's current 1-Year Share Buyback Ratio was 0.00%.
CHIX:DIMp's 1-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -2.5 * Ranked among companies with meaningful 1-Year Share Buyback Ratio only.
Sartorius Stedim Biotech (CHIX:DIMp) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Sartorius Stedim Biotech 1-Year Share Buyback Ratio Related Terms
CHIX:DIMP vs ISRG, BDX, MDLN: 1-Year Share Buyback Ratio Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech 1-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of 0.00 mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a 1-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #999999 out of 539 companies in the Medical Devices & Instruments industry.
Is Sartorius Stedim Biotech's 1-Year Share Buyback Ratio too high?
Sartorius Stedim Biotech's current 1-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Sartorius Stedim Biotech ranks #999999 out of 539 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's 1-Year Share Buyback Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #999999 out of 539 companies for 1-Year Share Buyback Ratio. This places Sartorius Stedim Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 1-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current 1-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €202.26, compared to a current price of €191.10 — trading 5.5% below its estimated fair value. The current 1-Year Share Buyback Ratio is 0.00. Sartorius Stedim Biotech's overall GF Score™ is 83/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current 1-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €191.10 is trading 5.5% below its estimated GF Value™ of €202.26.
GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.
Key valuation signals for CHIX:DIMP:
1-Year Share Buyback Ratio: 0.00
GF Value™: €202.26 vs. price of €191.10 (5.5% below fair value)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
83GF Score
Get the complete analysis for CHIX:DIMP
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
